Only in Titles

           Search results for: Anti_Human CD4_PE_Cy5_conjugate 2   

paperclip

#29652009   // Save this To Up

Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.

Polo-like kinase 1 (PLK1) is a critical molecule in the proliferation of several human cancers. Overexpression of PLK1 has been correlated with cancer cell proliferation and lower overall survival rates. Although PLK1 has been studied in various tumors, information regarding its expression in oral cancer and precancer is limited. Aims: This study is aimed at evaluating the expression of PLK1 in a potentially malignant and malignant disorder of the oral cavity, namely, oral submucous fibrosis (OSMF) and oral squamous cell carcinoma (OSCC), respectively, using the immunohistochemistry technique. It also intended to evaluate the association of the various histological grades of OSCC with the intensity of PLK1 expression.

2074 related Products with: Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis.

Oral cavity squamous cell Lung squamous cell carcin Cervix squamous cell carc Esophagus squamous cell c Esophagus squamous cell c Esophageal squamous cell Oral squamous cell cancer Esophagus squamous cell c Esophagus squamous cell c Kidney clear cell carcino Kidney clear cell carcino Esophagus squamous cell c

Related Pathways

paperclip

#29568205   // Save this To Up

Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey.

To understand the prevalence of hepatitis C virus (HCV) infection in blood donors over a nearly 27-year interval and to explore the factors that affect the outcome of HCV infection.

1896 related Products with: Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey.

Hepatitis B Core Antigen Hepatitis B Core Antigen Hepatitis B Core Antigen Hepatitis B Core Antigen Hepatitis C Virus antibod anti B human blood antige Blood Group Antibodies a anti B human blood group anti H n ab human blood a anti H inh human blood an MOUSE ANTI HUMAN CD173 - Anti 3 DG imidazolone Mon

Related Pathways

paperclip

#29551028   // Save this To Up

[Clinical efficacy and safety of porcine antihuman lymphocyte immunoglobulin in alternative donor allogeneic hematopoietic cell transplantation for severe aplastic anemia].

To compare eficacy and safety of porcine antihuman lymphocyte immunoglobulin (pALG) and rabbit antithymocyte immunoglobulin (rATG) as a part of alternative donor allogeneic hematopoietic stem cell transplantation (AD allo-HSCT) for severe aplastic anemia (SAA). The clinical data of 46 SAA patients received AD allo-HSCT from January 2006 to November 2016 were retrospectively analyzed. The cohort of patients were divided into two groups based on rATG or pALG as a part of conditioning regimen to compare implantation rate, transplantation related complications and outcome. In rATG group 30 patients achieved ANC reconstitution, 27 patients achieved PLT reconstitution. In pALG group all 16 patients achieved ANC and PLT reconstitutions. There were no significant differences between the two groups in terms of acute graft-versus-host disease (aGVHD) (=0.475), Ⅲ-Ⅳ grade aGVHD (=0.876), chronic GVHD (cGVHD) (=0.309), extensive cGVHD (=0.687), graft rejection (GR) (=0.928), bloodstream infection (=0.443), invasive fungal disease (=0.829), cytomegalovirus viremia (=0.095) respectively. Prospective 5-year overall survival (OS) in rATG and pALG groups were (75.1±8.2)% and (53.6±13.3)% with median follow-up of 14(2-102) and 23(4-63) months, respectively (=0.190). As a part of conditioning regimen, pALG could achieve similar efficacy as rATG, without increasing the incidences of transplantation complications such as GVHD, GR and infection, in the setting of AD allo-HSCT for SAA patients.

2228 related Products with: [Clinical efficacy and safety of porcine antihuman lymphocyte immunoglobulin in alternative donor allogeneic hematopoietic cell transplantation for severe aplastic anemia].

Lung squamous cell carcin Esophageal squamous cell Small cell lung carcinoma Non small cell lung carci Non small cell lung carci Lung small cell carcinoma Multiple lung carcinoma ( Lung large cell carcinoma Oral squamous cell cancer Non-small cell lung cance Cellufine Formyl , 50 ml Cellufine Formyl Media

Related Pathways

paperclip

#29479956   // Save this To Up

Comparison of standard agglutination tests, enzyme immunoassay, and Coombs gel test used in laboratory diagnosis of human brucellosis

Background/aim: It was aimed to evaluate the results of Rose Bengal (RB), ELISA total tests (IgM and IgG), and the Brucella Coombs gel test (BCGT), which are used as screening tests, with the combined results of a tube agglutination test (standard Wright test: SWT) and a tube agglutination test with antihuman globulin (AHG TAT). Materials and methods: Samples from 97 patients prediagnosed with brucellosis (age ≥18 years) were screened with RB, ELISA, and BCGT. SWT < 160 samples and RB-negative but ELISA- or BCGT-positive samples were tested by AHG TAT. SWT ≥ 160 or AHG TAT ≥ 160 was taken as reference. Results: Thirty-two of 56 RB-positive samples and one RB-negative but ELISA- and BCGT-positive sample were found to be ≥160 with SWT or AHG TAT. Sensitivity, specificity, accuracy, and agreement (kappa) values according to SWT ≥ 160 or AHG TAT ≥ 160 positivity were as follows, respectively: RB 96.9%, 62.5%, 74.2%, and 0.509; ELISA total 100%, 60.9%, 74.2%, and 0.515; BCGT test 97%, 70.3%, 79.4%, and 0.594. Conclusion: Sensitivities of the screening tests are similar, but positivities should be confirmed by more specific tests. Positive samples from screening tests should be tested with AHG if the SWT value is <160.

2218 related Products with: Comparison of standard agglutination tests, enzyme immunoassay, and Coombs gel test used in laboratory diagnosis of human brucellosis

Beta Amyloid (42) ELISA K Alkaline Phospatase (ALP) Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Beta Amyloid (1 40) ELISA Human Beta 2 microglobuli Mouse Anti-Human Bcl-10 [ Mouse Anti-Human CD65s [+ Mouse Anti-Human TREM-1, Human IgG (total) ELISA K HBeAg test strip, Infecti Anti-HBeAg (HBeAb) test s

Related Pathways

paperclip

#29397848   // Save this To Up

[Positive Distribution Rate of Coombs Test in Patients with Clinical Anemia and Blood Transfusion and Its Effect on Clinical Blood Transfusion].

To study the positive distribution rate of Coombs test in patients with clinical anemia and blood transfusion, and its effect on clinical blood transfusion.

1432 related Products with: [Positive Distribution Rate of Coombs Test in Patients with Clinical Anemia and Blood Transfusion and Its Effect on Clinical Blood Transfusion].

C Peptide ELISA Kit, Rat Anti beta3 AR Human, Poly Multiple organ tumor tiss Embryonal tumor test tiss Embryonal tumor test tiss Endocrine organ cancer te Stomach cancer test tissu Stomach cancer test tissu Stomach cancer test tissu Esophageal cancer test ti Esophagus carcer test tis Esophageal cancer test ti

Related Pathways

paperclip

#29259704   // Save this To Up

Effect of human umbilical cord blood stem cell transplantation on oval cell response in 2-AAF/CCL4 liver injury model: experimental immunohistochemical study.

Oval cells, specific liver progenitors, are activated in response to injury. The human umbilical cord blood (hUCB) is a possible source of transplantable hepatic progenitors and can be used in cases of severe liver injury. We detected the effect of hUCB stem cell transplantation on natural response of oval cells to injury.

2544 related Products with: Effect of human umbilical cord blood stem cell transplantation on oval cell response in 2-AAF/CCL4 liver injury model: experimental immunohistochemical study.

Macrophage Colony Stimula Macrophage Colony Stimula Human Cord Blood CD34+ Ce CELLKINES Natural Human I Human Stem Cell Factor SC Anti beta3 AR Human, Poly Rabbit Anti-Cell death in Rabbit Anti-Cell death in Human Umbilical Vein Endo GFP Expressing Human Umbi Mitochondria GFP Tag Huma Plasma Membrane GFP Tag H

Related Pathways

paperclip

#29257317   // Save this To Up

Crosstalk between human endometrial stromal cells and decidual NK cells promotes decidualization in vitro by upregulating IL‑25.

Embryo implantation is essential for a successful pregnancy, and leads to the decidualization of endometrial stromal cells (ESCs) in the secretory phase of the menstrual cycle. It has previously been demonstrated that decidual stromal cells (DSCs) co‑express interleukin (IL)‑25/IL‑17RB and that IL‑25 further promotes the proliferation of DSCs via activating c‑Jun n‑terminal kinase and protein kinase B signals, therefore the present study primarily focused on the role of IL‑25 in the process of decidualization in vitro. It was demonstrated that the expression of IL‑25/IL‑17RB in ESCs was decreased compared with DSCs. In addition, following decidualization, the expression levels of IL‑25/IL‑17RB in ESCs were significantly elevated. Recombinant human (rh) IL‑25 promoted the decidualization of ESCs in the presence of 8‑bromoadenosine 3',5'‑cyclic monophosphate sodium salt and 6α‑methyl17α‑acetoxyprogesterone, which was partially inhibited by anti‑human IL‑25 neutralizing antibody (anti‑IL‑25) or anti‑IL‑17RB. In addition, decidual natural killer (dNK) cells not only secreted IL‑25, however also further accelerated the decidualization in vitro. Therefore, these findings indicated that ESCs differentiate into DSCs in the presence of ovarian hormones, resulting in the upregulation of IL‑25/IL‑17RB expression in ESCs. Furthermore, IL‑25 secreted by ESCs and dNK cells further facilitates the decidualization of ESCs, which may form a positive feedback mechanism at the maternal‑fetal interface and thus contribute to the establishment and maintenance of normal pregnancy.

2609 related Products with: Crosstalk between human endometrial stromal cells and decidual NK cells promotes decidualization in vitro by upregulating IL‑25.

Recombinant Human IL-4 [f Recombinant Human IL-6 (I anti CD45 RA B cells, T c Mouse Anti-Human Fibrobla Mouse Anti-Human Fibrobla Mouse Anti-Human Follicul Mouse Anti-Human Follicul Anti C Reactive Protein A Epidermal Growth Factor ( Epidermal Growth Factor ( Human Interleukin-17E (IL Macrophage Colony Stimula

Related Pathways

  •  
  • No related Items
paperclip

#29163501   // Save this To Up

Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.

Optimal adoptive cell therapy (ACT) should contribute to effective cancer treatment. The unique ability of natural killer (NK) cells to kill cancer cells independent of major histocompatibility requirement makes them suitable as ACT tools. Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2 breast cancer. However, it has limited effectiveness and possible severe cardiotoxicity. Given that Herceptin may increase the cytotoxicity of lymphocytes, we explored the possible augmentation of NK cell cytotoxicity against HER2 breast cancer cells by Herceptin. We demonstrated that Herceptin could interact with CD16 on NK cells to expand the cytotoxic NK (specifically, CD56) cell population. Additionally, Herceptin increased NK cell migration and cytotoxicity against HER2 breast cancer cells. In a pilot study, Herceptin-treated NK cells shrunk lung nodular metastasis in a woman with HER2 breast cancer who could not tolerate the cardiotoxic side effects of Herceptin. Our findings support the therapeutic potential of Herceptin-treated NK cells in patients with HER2 and Herceptin-intolerant breast cancer.

1475 related Products with: Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.

Epidermal Growth Factor ( Epidermal Growth Factor ( Mouse Anti-Human CD94 (Na Epidermal Growth Factor ( Epidermal Growth Factor ( Human Epidermal Growth Fa Macrophage Colony Stimula Macrophage Colony Stimula anti Transferrin receptor GFP Expressing Human Umbi RFP Expressing Human Umbi GFP Expressing Human Brai

Related Pathways

paperclip

#28970677   // Save this To Up

Red cell alloimmunization in repeatedly transfused patients.

Repeated blood transfusions can result in the production of alloantibodies against one or more red cell antigens, which complicates subsequent transfusions. Aims: The study was done to find incidence of various red cell alloantibodies; to determine the type of alloantibody; to identify the factors such as frequency of transfusion, splenectomy status, donor ethnicity and gender and their association with the development of antibody in repeatedly transfused patients.

1171 related Products with: Red cell alloimmunization in repeatedly transfused patients.

Nile Red, A lipophilic dy Alamar Blue™, REDOX ind Alamar Blue™, REDOX ind anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl CELLKINES Natural Human I CELLKINES INTERLEUKIN 2 ( CELLKINES INTERLEUKIN 2 ( Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu

Related Pathways

paperclip

#28939747   // Save this To Up

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and haploidentical natural killer (NK) cells. Children with recurrent/refractory neuroblastoma received up to six courses of hu14.18K322A (40 mg/m/dose, days 2-5), GM-CSF, and IL2 with chemotherapy: cyclophosphamide/topotecan (courses 1,2), irinotecan/temozolomide (courses 3,4), and ifosfamide/carboplatin/etoposide (courses 5,6). Parentally derived NK cells were administered with courses 2, 4, and 6. Serum for pharmacokinetic studies of hu14.18K322A, soluble IL2 receptor alpha (sIL2Rα) levels, and human antihuman antibodies (HAHA) were obtained. Thirteen heavily pretreated patients (9 with prior anti-GD2 therapy) completed 65 courses. One patient developed an unacceptable toxicity (grade 4 thrombocytopenia >35 days). Four patients discontinued treatment for adverse events (hu14.18K322A allergic reaction, viral infection, surgical death, second malignancy). Common toxicities included grade 3/4 myelosuppression (13/13 patients) and grade 1/2 pain (13/13 patients). Eleven patients received 29 NK-cell infusions. The response rate was 61.5% (4 complete responses, 1 very good partial response, 3 partial responses) and five had stable disease. The median time to progression was 274 days (range, 239-568 days); 10 of 13 patients (77%) survived 1 year. Hu14.18K322A pharmacokinetics was not affected by chemotherapy or HAHA. All patients had increased sIL2Rα levels, indicating immune activation. Chemotherapy plus hu14.18K322A, cytokines, and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed and newly diagnosed neuroblastoma. .

1768 related Products with: A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

Anti C Reactive Protein A Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl Anti 3 DG imidazolone Mon Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1G11) Mouse Anti-Insulin(1G11)

Related Pathways